Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review
- PMID: 32902367
- DOI: 10.1080/17476348.2020.1820329
Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): a practical comprehensive literature review
Abstract
Introduction: The exponential growth of SARS-CoV-2 virus transmission during the first months of 2020 has placed substantial pressure on most health systems around the world. The complications derived from the novel coronavirus disease (COVID-19) vary due to comorbidities, sex and age, with more than 50% of the patients requiring some level of intensive care developing acute respiratory distress syndrome (ARDS). The authors carried out an extensive and comprehensive literature review on SARS-CoV-2 infection, the clinical, pathological, and radiological presentation as well as the current treatment strategies.
Areas covered: Various complications caused by SARS-CoV-2 infection have been identified, the most lethal being the acute respiratory distress syndrome, caused most likely by the presence of severe immune cell response and the concomitant alveolus inflammation. The new treatment strategies are updated, and the analysis of the physiopathology is included in this review.
Expert opinion: ARDS is one of the most frequent complications in patients with COVID-19. Information regarding the etiology and physiopathology are still unfolding and for the prevention and amelioration, good clinical management, adequate ventilatory support and the use of systemic corticoids seem to be the most efficient way to reduce mortality and to reduce hospital lengths.
Keywords: ARDS; Acute Respiratory Distress Syndrome; COVID-19; coronavirus; expert review.
Similar articles
-
Ventilation management in acute respiratory failure related to COVID-19 versus ARDS from another origin - a descriptive narrative review.Expert Rev Respir Med. 2021 Aug;15(8):1013-1023. doi: 10.1080/17476348.2021.1913060. Epub 2021 Apr 13. Expert Rev Respir Med. 2021. PMID: 33847219 Free PMC article. Review.
-
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.Anal Cell Pathol (Amst). 2020 Nov 20;2020:1939768. doi: 10.1155/2020/1939768. eCollection 2020. Anal Cell Pathol (Amst). 2020. PMID: 33274176 Free PMC article. Review.
-
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization.Eur J Heart Fail. 2020 Dec;22(12):2228-2237. doi: 10.1002/ejhf.2058. Epub 2020 Dec 7. Eur J Heart Fail. 2020. PMID: 33200458 Free PMC article.
-
Pathogenesis-directed therapy of 2019 novel coronavirus disease.J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33073355 Review.
-
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.Stem Cell Res Ther. 2021 Jan 29;12(1):91. doi: 10.1186/s13287-021-02165-4. Stem Cell Res Ther. 2021. PMID: 33514427 Free PMC article. Clinical Trial.
Cited by
-
A Systematic Review and Quality Evaluation of Studies on Long-Term Sequelae of COVID-19.Healthcare (Basel). 2022 Nov 24;10(12):2364. doi: 10.3390/healthcare10122364. Healthcare (Basel). 2022. PMID: 36553888 Free PMC article. Review.
-
Predictive Factors of Mortality in Patients with Severe COVID-19 Treated in the Intensive Care Unit: A Single-Center Study in Vietnam.Pulm Ther. 2023 Sep;9(3):377-394. doi: 10.1007/s41030-023-00231-1. Epub 2023 Jul 7. Pulm Ther. 2023. PMID: 37415031 Free PMC article.
-
Coronavirus Receptor Expression Profiles in Human Mast Cells, Basophils, and Eosinophils.Cells. 2024 Jan 17;13(2):173. doi: 10.3390/cells13020173. Cells. 2024. PMID: 38247864 Free PMC article.
-
High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU.PLoS One. 2022 Mar 31;17(3):e0262423. doi: 10.1371/journal.pone.0262423. eCollection 2022. PLoS One. 2022. PMID: 35358185 Free PMC article.
-
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.Thorax. 2023 Aug;78(8):816-824. doi: 10.1136/thorax-2022-219668. Epub 2023 Apr 6. Thorax. 2023. PMID: 37024277 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous